Discovery of 6-Methoxy-2-(4-methoxyphenyl)-1-benzothiophene

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Product Details of 63675-74-1, you can also check out more blogs about63675-74-1

Chemistry is an experimental science, and the best way to enjoy it and learn about it is performing experiments. Product Details of 63675-74-1. Introducing a new discovery about 63675-74-1, Name is 6-Methoxy-2-(4-methoxyphenyl)-1-benzothiophene

The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-positive (ER+) breast cancer. Here, we describe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-molecule ERalpha degraders based on the proteolysis targeting chimeras (PROTAC) concept. Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 (32). ERD-308 achieves DC50 (concentration causing 50% of protein degradation) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, respectively, and induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines. Significantly, ERD-308 induces more complete ER degradation than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells. Further optimization of ERD-308 may lead to a new therapy for advanced ER+ breast cancer.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Product Details of 63675-74-1, you can also check out more blogs about63675-74-1

Reference：
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem